<DOC>
	<DOCNO>NCT02904850</DOCNO>
	<brief_summary>Several argument favor therapeutic monitoring erlotinib , therefore , pharmacokinetic ( PK ) prepare use data literature . This model must validate concentration achieve practice . This preliminary study implementation randomize trial confirm therapeutic monitoring erlotinib model .</brief_summary>
	<brief_title>Validation Kinetic Model Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>All patient receive treatment erlotinib monotherapy locally advance metastatic NSCLC either first line patient activate mutation receptor EGFR patient stable disease 4 cycle standard firstline chemotherapy platinum failure least one prior chemotherapy regimen Age &gt; 18 year Subject sign informed consent Treatment initiate least 7 day dosage change least 7 day Contraindication use drug Subject exclusion period ( determine previous study progress ) Inability give inform information ( subject emergency situation , difficulty understand subject , ... ) Subject judicial protection Subject tutorship curatorship Pregnancy ( woman childbearing age without contraception ) Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>locally advanced metastatic</keyword>
	<keyword>erlotinib monotherapy</keyword>
</DOC>